Radiopharm Theranostics maintains a "Hold" rating as its radiotherapeutic pipeline advances, with key data readouts expected in 2026. Click here to read.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results